Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

281. Heterogeneous Contribution of Insulin Sensitivity and Secretion Defects to Gestational Diabetes Mellitus (PubMed)

Heterogeneous Contribution of Insulin Sensitivity and Secretion Defects to Gestational Diabetes Mellitus To characterize physiologic subtypes of gestational diabetes mellitus (GDM).Insulin sensitivity and secretion were estimated in 809 women at 24-30 weeks' gestation, using oral glucose tolerance test-based indices. In women with GDM (8.3%), defects in insulin sensitivity or secretion were defined below the 25th percentile in women with normal glucose tolerance (NGT). GDM subtypes were defined (...) based on the defect(s) present.Relative to women with NGT, women with predominant insulin sensitivity defects (51% of GDM) had higher BMI and fasting glucose, larger infants (birth weight z score 0.57 [-0.01 to 1.37] vs. 0.03 [-0.53 to 0.52], P = 0.001), and greater risk of GDM-associated adverse outcomes (57.6 vs. 28.2%, P = 0.003); differences were independent of BMI. Women with predominant insulin secretion defects (30% of GDM) had BMI, fasting glucose, infant birth weights, and risk of adverse

Full Text available with Trip Pro

2016 EvidenceUpdates

282. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. (PubMed)

Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Short-acting insulin analogue use for people with diabetes is still controversial, as reflected in many scientific debates.To assess the effects of short-acting insulin analogues versus regular human insulin in adults with type 1 diabetes.We carried out the electronic searches through Ovid simultaneously searching the following databases: Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process & Other Non (...) -Indexed Citations, Ovid MEDLINE(R) Daily and Ovid OLDMEDLINE(R) (1946 to 14 April 2015), EMBASE (1988 to 2015, week 15), the Cochrane Central Register of Controlled Trials (CENTRAL; March 2015), ClinicalTrials.gov and the European (EU) Clinical Trials register (both March 2015).We included all randomised controlled trials with an intervention duration of at least 24 weeks that compared short-acting insulin analogues with regular human insulins in the treatment of adults with type 1 diabetes who were

2016 Cochrane

283. Investigating the Relationship between Insulin-like Growth Factor-1 (IGF-1) in diabetic mother’s breast milk and the blood serum of their babies (PubMed)

Investigating the Relationship between Insulin-like Growth Factor-1 (IGF-1) in diabetic mother’s breast milk and the blood serum of their babies Since research investigating IGF-1 levels in breast milk are few, the goal of this study was to analyze the IGF-1 levels in the breast milk of diabetic mothers as well as in the serum of their newborn babies and to identify what relationship exists between blood serum and IGF-1 milk levels through patient measurement of mothers and their babies.This

Full Text available with Trip Pro

2016 Electronic physician

284. Acanthosis Nigricans and Insulin Resistance. (PubMed)

Acanthosis Nigricans and Insulin Resistance. 27305209 2016 06 30 2016 06 16 1533-4406 374 24 2016 Jun 16 The New England journal of medicine N. Engl. J. Med. IMAGES IN CLINICAL MEDICINE. Acanthosis Nigricans and Insulin Resistance. e31 10.1056/NEJMicm1508730 Lauria Marcio W MW Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte-MG, Brazil marciowlauria@gmail.com. Saad Mario J MJ Universidade Estadual de Campinas, Campinas-SP, Brazil. eng Case Reports Journal Article (...) United States N Engl J Med 0255562 0028-4793 0 Autoantibodies EC 2.7.10.1 Receptor, Insulin AIM IM Acanthosis Nigricans etiology pathology Adult Autoantibodies blood Autoimmune Diseases complications diagnosis Female Hirsutism etiology Humans Hyperglycemia etiology Hyperinsulinism etiology Insulin Resistance Receptor, Insulin immunology 2016 6 16 6 0 2016 6 16 6 0 2016 7 1 6 0 ppublish 27305209 10.1056/NEJMicm1508730

Full Text available with Trip Pro

2016 NEJM

285. Insulin resistance: vascular function and exercise (PubMed)

Insulin resistance: vascular function and exercise Insulin resistance associated with metabolic syndrome and Type 2 diabetes mellitus is an epidemic metabolic disorder, which increases the risk of cardiovascular complications. Impaired vascular endothelial function is an early marker for atherosclerosis, which causes cardiovascular complications. Both experimental and clinical studies indicate that endothelial dysfunction in vasculatures occurs with insulin resistance. The associated (...) physiological mechanisms are not fully appreciated yet, however, it seems that augmented oxidative stress, a physiological imbalance between oxidants and antioxidants, in vascular cells is a possible mechanism involved in various vascular beds with insulin resistance and hyperglycemia. Regardless of the inclusion of resistance exercise, aerobic exercise seems to be beneficial for vascular endothelial function in both large conduit and small resistance vessels in both clinical and experimental studies

Full Text available with Trip Pro

2016 Integrative medicine research

286. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. (PubMed)

Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Diabetes results in a rise in blood glucose above normal physiological levels; if untreated this may cause damage to many systems including the cardiovascular and renal systems. Pregnancy increases resistance to insulin action; for those women who have pre-gestational diabetes, this results in an increasing insulin requirement. There are several methods of administering insulin (...) . Conventionally, insulin has been administered subcutaneously, formally referred to as intensive conventional treatment, but now more usually referred to as multiple daily injections (MDI). An alternative method of insulin administration is the continuous subcutaneous insulin infusion pump (CSII).To compare CSII with MDI of insulin for pregnant women with pre-existing and gestational diabetes.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 March 2016) and reference lists

Full Text available with Trip Pro

2016 Cochrane

287. The Clinical and Economic Impact of the V-Go® Disposable Insulin Delivery Device for Insulin Delivery in Patients with Poorly Controlled Diabetes at High Risk (PubMed)

The Clinical and Economic Impact of the V-Go® Disposable Insulin Delivery Device for Insulin Delivery in Patients with Poorly Controlled Diabetes at High Risk Diabetes is a chronic condition and when poorly controlled can lead to complications and death. Patients with glycated hemoglobin (A1C) measures >9 % are at significant risk for diabetes-related complications impacting the patient's quality of life and imposing higher costs on the healthcare system. A1C reductions of 1 % or greater (...) in this population have demonstrated substantial health and economic benefits. Reducing the percent of patients at risk is an essential component of quality-care measures established for patients with diabetes.To evaluate if switching patients prescribed subcutaneous insulin injections to V-Go for insulin delivery would impact clinical and economic parameters in patients with poorly controlled diabetes (A1C > 9 %).The study was a retrospective analysis using data extracted from the electronic medical records

Full Text available with Trip Pro

2016 Drugs - real world outcomes

288. Insulin and oral agents for managing cystic fibrosis-related diabetes. (PubMed)

Insulin and oral agents for managing cystic fibrosis-related diabetes. The Cystic Fibrosis Foundation recommends both short-term and long-acting insulin therapy when cystic fibrosis-related diabetes has been diagnosed. Diagnosis is based on: an elevated fasting blood glucose level greater than 6.94 mmol/liter (125 mg/deciliter); or oral glucose tolerance tests greater than 11.11 mmol/liter (200 mg/deciliter) at two hours; or symptomatic diabetes for random glucose levels greater than 11.11 mmol (...) /liter (200 mg/deciliter); or glycated hemoglobin levels of at least 6.5%.To establish the effectiveness of insulin and oral agents for managing diabetes in people with cystic fibrosis in relation to blood sugar levels, lung function and weight management.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference

2016 Cochrane

289. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naive adults with Type 2 diabetes (PubMed)

Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naive adults with Type 2 diabetes To evaluate the efficacy and safety of twice-daily insulin degludec/insulin aspart vs. twice-daily biphasic insulin aspart 30 in people with Type 2 diabetes mellitus who were naïve to insulin.In this 26-week, multinational, open-label, controlled, two-arm, parallel-group, treat (...) -to-target trial, participants [mean (± sd) age 58.9 (±8.9) years, duration of diabetes 9.5 (±5.9) years, HbA1c 68 (±8.7) mmol/mol or 8.4 (±0.8)% and BMI 31.2 (±4.2) kg/m(2) ) were randomized (1:1) to insulin degludec/insulin aspart (n = 197) or biphasic insulin aspart 30 (n = 197), administered with breakfast and the main evening meal, titrated to a self-monitored plasma glucose target > 3.9 and ≤ 5.0 mmol/l.The mean HbA1c was reduced to 49 mmol/mol (6.6%) with insulin degludec/insulin aspart and 48

Full Text available with Trip Pro

2016 EvidenceUpdates Controlled trial quality: uncertain

290. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1) (PubMed)

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1) To compare efficacy and safety of new insulin glargine 300 U/ml (Gla-300) with that of insulin glargine 100 U/ml (Gla-100) in Japanese adults with type 1 diabetes.The EDITION JP 1 study (NCT01689129) was a 6-month, multicentre, open-label, phase III study. Participants (n = 243) were (...) randomized to Gla-300 or Gla-100 while continuing mealtime insulin. Basal insulin was titrated with the aim of achieving a fasting self-monitored plasma glucose target of 4.4-7.2 mmol/l. The primary endpoint was change in glycated haemoglobin (HbA1c) over 6 months. Safety measures included hypoglycaemia and change in body weight.Gla-300 was non-inferior to Gla-100 for the primary endpoint of HbA1c change over the 6-month period {least squares [LS] mean difference 0.13 % [95 % confidence interval (CI

Full Text available with Trip Pro

2016 EvidenceUpdates Controlled trial quality: predicted high

291. [Insulin therapy in patients with cystic fibrosis in the pre-diabetes stage: a systematic review]. (PubMed)

[Insulin therapy in patients with cystic fibrosis in the pre-diabetes stage: a systematic review]. To elucidate whether insulin is effective or not in patients with cystic fibrosis before the diabetes mellitus phase.The study was performed according to the Prisma method between August and September 2014, using the PubMed, Embase, Lilacs and SciELO databases. Prospective studies published in English, Portuguese and Spanish from 2002 to 2014, evaluating the effect of insulin on weight parameters (...) , body mass index and pulmonary function in patients with cystic fibrosis, with a mean age of 17.37 years before the diabetes mellitus phase were included.Eight articles were identified that included 180 patients undergoing insulin use. Sample size ranged from 4 to 54 patients, with a mean age ranging from 12.4 to 28 years. The type of follow-up, time of insulin use, the dose and implementation schedule were very heterogeneous between studies.There are theoretical reasons to believe that insulin has

Full Text available with Trip Pro

2016 Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo

292. Hepatitis C Virus, Insulin Resistance, and Steatosis (PubMed)

Hepatitis C Virus, Insulin Resistance, and Steatosis Hepatitis C virus (HCV) is one of the main causes of liver disease worldwide. Liver steatosis is a common finding in many hepatic and extrahepatic disorders, the most common being metabolic syndrome (MS). Over time, it has been shown that the frequent coexistence of these two conditions is not coincidental, since many epidemiological, clinical, and experimental studies have indicated HCV to be strongly associated with liver steatosis (...) and numerous metabolic derangements. Here, we present an overview of publications that provide clinical evidence of the metabolic effects of HCV and summarize the available data on the pathogenetic mechanisms of this association. It has been shown that HCV infection can induce insulin resistance (IR) in the liver and peripheral tissues through multiple mechanisms. Substantial research has suggested that HCV interferes with insulin signaling both directly and indirectly, inducing the production of several

Full Text available with Trip Pro

2016 Journal of clinical and translational hepatology

293. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. (PubMed)

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. Achieving glycemic control remains a challenge for patients with type 2 diabetes, even with insulin therapy.To assess whether a fixed ratio of insulin degludec/liraglutide was noninferior to continued titration of insulin glargine in patients with uncontrolled type 2 diabetes treated with insulin glargine

Full Text available with Trip Pro

2016 JAMA Controlled trial quality: predicted high

294. Comparative study between two recombinant human NPH insulin formulations for the treatment of type 2 diabetes mellitus. (PubMed)

Comparative study between two recombinant human NPH insulin formulations for the treatment of type 2 diabetes mellitus. To compare the effects of the neutral protamine Hagedorn (NPH) recombinant human insulin formulations Gansulin and Humulin N® on the glycemic control of patients with type 2 diabetes mellitus (T2DM).Prospective, double-blind, randomized, parallel, single-center study of 37 individuals with T2DM treated with NPH insulin formulations. The Tukey-Kramer test for multiple (...) comparisons, the Wilcoxon paired comparison test and the Chi-Square test were used for the statistical analyses. The significance level was set at 5% (p < 0.05).The NPH insulin formulations Humulin and Gansulin similarly reduced the HbA1c levels observed at the end of the study compared with the values obtained at the beginning of the study. In the Humulin group, the initial HbA1c value of 7.91% was reduced to 6.56% (p < 0.001), whereas in the Gansulin group, the reduction was from 8.18% to 6.65% (p

Full Text available with Trip Pro

2016 Archives of endocrinology and metabolism Controlled trial quality: uncertain

295. Insulin Resistance and a Long, Strange Trip. (PubMed)

Insulin Resistance and a Long, Strange Trip. 26886417 2016 04 13 2018 12 02 1533-4406 374 14 2016 Apr 07 The New England journal of medicine N. Engl. J. Med. Insulin Resistance and a Long, Strange Trip. 1378-9 10.1056/NEJMe1600962 Semenkovich Clay F CF From the Division of Endocrinology, Metabolism and Lipid Research, Washington University, St. Louis. eng Editorial Comment 2016 02 17 United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 0 Thiazolidinediones AIM IM N Engl J Med (...) . 2016 Apr 7;374(14):1321-31 26886418 Female Fractures, Bone chemically induced Humans Hypoglycemic Agents therapeutic use Insulin Resistance Ischemic Attack, Transient drug therapy Male Myocardial Infarction prevention & control Stroke drug therapy Thiazolidinediones therapeutic use 2016 2 18 6 0 2016 2 18 6 0 2016 4 14 6 0 ppublish 26886417 10.1056/NEJMe1600962

2016 NEJM

296. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. (PubMed)

Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. Diabetic ketoacidosis (DKA) is an acute, life-threatening complication of uncontrolled diabetes that mainly occurs in individuals with autoimmune type 1 diabetes, but it is not uncommon in some people with type 2 diabetes. The treatment of DKA is traditionally accomplished by the administration of intravenous infusion of regular insulin that is initiated in the emergency department and continued in an intensive care unit (...) or a high-dependency unit environment. It is unclear whether people with DKA should be treated with other treatment modalities such as subcutaneous rapid-acting insulin analogues.To assess the effects of subcutaneous rapid-acting insulin analogues for the treatment of diabetic ketoacidosis.We identified eligible trials by searching MEDLINE, PubMed, EMBASE, LILACS, CINAHL, and the Cochrane Library. We searched the trials registers WHO ICTRP Search Portal and ClinicalTrials.gov. The date of last search

Full Text available with Trip Pro

2016 Cochrane

297. Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines

Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines | CADTH.ca Find the information you need Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness (...) and Guidelines Published on: December 10, 2015 Project Number: RC0731-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of insulin pumps versus multiple daily injections for adults with type 1 diabetes? What is the comparative clinical effectiveness of insulin pump models with continuous glucose monitors versus standard insulin pumps for adults with type 1 diabetes? What is the cost-effectiveness

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

298. Subcutaneous Insulin in the Treatment of Diabetic Ketoacidosis in the Pediatric Population

Subcutaneous Insulin in the Treatment of Diabetic Ketoacidosis in the Pediatric Population "Subcutaneous Insulin in the Treatment of Diabetic Ketoacidosis in the " by Lauren A. Ljunghag < > > > > > Title Author Date of Graduation Summer 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Diabetic ketoacidosis or DKA is an acute and fatal disease that is highly prevalent in the pediatric population. The current gold (...) standard of treatment is continuous intravenous regular insulin (CIRI), which requires admission to the intensive care unit (ICU) and is a substantial cost to the patient. Alternate routes of insulin administration, such as subcutaneous (SQ) insulin, do not require ICU admission. If SQ insulin is found to be safe and efficacious for the treatment of DKA, this treatment modality could replace continuous IV regular insulin, and therefore decrease the need for ICU admission and cost of stay. Methods

2016 Pacific University EBM Capstone Project

299. Randomized clinical trial: Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus

Randomized clinical trial: Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus Article

2016 Evidence-Based Medicine (Requires free registration)

300. Randomised controlled trial: Blood glucose monitoring had no impact on distress or self-efficacy in people with non-insulin-treated type 2 diabetes

Randomised controlled trial: Blood glucose monitoring had no impact on distress or self-efficacy in people with non-insulin-treated type 2 diabetes Blood glucose monitoring had no impact on distress or self-efficacy in people with non-insulin-treated type 2 diabetes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Blood glucose monitoring had no impact on distress or self-efficacy in people with non-insulin-treated type 2 diabetes

2016 Evidence-Based Medicine (Requires free registration)